COMPOSITION AND METHODS FOR TREATING CANCER AND IMMUNE DISORDERS USING VEILLONELLA BACTERIA
Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents.
1 - 161 . (canceled)
162 . A method of treating an immune disorder in a subject comprising orally administering to the subject a pharmaceutical composition comprising Veillonella parvula Strain B (ATCC Accession Number PTA-125691) and a pharmaceutically acceptable carrier.
163 . The method of claim 162 , wherein the Veillonella parvula Strain B (ATCC Accession Number PTA-125691) and the pharmaceutically acceptable carrier are within an enteric coating.
164 . The method of claim 162 , wherein the immune disorder is atopic dermatitis, psoriasis, or asthma.
165 . The method of claim 162 , wherein at least 50% of the bacteria in the pharmaceutical composition are Veillonella parvula Strain B (ATCC Accession Number PTA-125691).
166 . The method of claim 162 , wherein at least 95% of the bacteria in the pharmaceutical composition are Veillonella parvula Strain B (ATCC Accession Number PTA-125691).
167 . The method of claim 162 , wherein at least 99% of the bacteria in the pharmaceutical composition are Veillonella parvula Strain B (ATCC Accession Number PTA-125691).
168 . The method of claim 162 , wherein the pharmaceutical composition comprises at least 1×10 6 colony forming units (CFUs) of Veillonella parvula Strain B (ATCC Accession Number PTA-125691.
169 . The method of claim 162 , wherein the pharmaceutical composition comprises live bacteria.
170 . The method of claim 162 , wherein the pharmaceutical composition comprises killed bacteria.
171 . The method of claim 162 , wherein the pharmaceutical composition comprises irradiated bacteria.
172 . The method of claim 171 , wherein the irradiated bacteria comprises gamma irradiated bacteria.
173 . The method of claim 163 , wherein the pharmaceutical composition is formulated as an enteric coated capsule.
174 . The method of claim 163 , wherein the pharmaceutical composition is formulated as an enteric coated tablet.
175 . The method of claim 163 , wherein the enteric coating is a coating for duodenal release at a pH of about 5.5-6.2.
176 . The method of claim 163 , wherein the enteric coating is a coating for release in the ileum at a pH of about 7.2-7.2.
177 . The method of claim 163 , wherein the enteric coating is a coating for release in the colon at a pH of about 5.6-7.2.
178 . The method of claim 162 , wherein the Veillonella parvula Strain B (ATCC Accession Number PTA-125691) is freeze-dried.
179 . The method of claim 62 , wherein the method further comprises administering to the subject an additional therapeutic.
180 . The method of claim 179 , wherein the additional therapeutic is an antibiotic.
181 . The method of claim 179 , wherein the additional therapeutic is an anti-inflammatory agent.